Fortress Biotech, Inc.

Contributing Author

Recent Articles by Fortress Biotech, Inc.

Oct-21	Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout FBIO GlobeNewswire
Oct-01	Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing FBIO GlobeNewswire
Oct-01	Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101 FBIO GlobeNewswire
Sep-02	Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference FBIO GlobeNewswire
Aug-14	Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights FBIO GlobeNewswire
May-30	Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics FBIO GlobeNewswire
May-15	Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights FBIO GlobeNewswire
May-07	Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference FBIO GlobeNewswire